Xencor, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XNCR research report →
Range $40 – $46
Price Chart
About the company
Xencor Inc. , a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders.
- CEO
- Bassil I. Dahiyat
- IPO
- 2013
- Employees
- 260
- HQ
- Pasadena, CA, US
Get TickerSpark's AI analysis on XNCR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.50B
- P/E
- -21.18
- PEG
- 0.29
- P/S
- 12.45
- P/B
- 4.52
- EV/EBITDA
- -31.58
- Div Yield
- 0.00%
- Gross Margin
- 97.43%
- Op Margin
- -72.67%
- Net Margin
- -58.79%
- ROE
- -21.29%
- ROIC
- -20.19%
Latest fiscal year · YoY change
- Revenue
- $125.58M+13.7%
- Gross Profit
- $115.06M+198.2%
- Op Income
- $-177,502,000
- Net Income
- $-91,923,000+60.5%
- EPS
- $-1.24+65.4%
- OCF Growth
- +33.2%
- FCF Growth
- +33.6%
- 52W High
- $40.60
- 52W Low
- $10.38
- 50D MA
- $28.09
- 200D MA
- $18.56
- Beta
- 0.90
- RSI (14)
- 53
- Avg Volume
- 1.53M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Xencor ended 2023 with a strengthened balance sheet and is sharpening its pipeline around solid-tumor bispecifics, while vudalimab showed encouraging early prostate cancer activity but still needs more data to define its path.· February 27, 2024
- Ended 2023 with $697 million in cash and expects runway into 2027 after a partial monetization of Ultomiris and Monjuvi royalties.
- Pipeline focus is shifting toward solid-tumor T-cell engagers, including XmAb819, XmAb808 and XmAb541, while investment in cytokine candidates is being reduced.
- Vudalimab monotherapy in heavily pretreated mCRPC showed a 35% RECIST response rate, 50% disease control rate and 25% PSA90 rate, with generally checkpoint-like safety.
- Management said it will keep enrolling both the monotherapy and docetaxel-combination prostate cohorts and expects to have more clarity later in 2024 / by year-end.
- The company does not plan to call initial ENPP3 data yet and is waiting for more patient follow-up before disclosing.
- Protocol for the prostate combination study was amended to remove carboplatin except in aggressive-variant disease, with investigators reporting better tolerability so far.
The call did not include quarterly revenue, EPS, or gross margin figures. Management did state that Xencor ended 2023 with $697 million in cash and expects runway into 2027. For vudalimab’s prostate monotherapy cohort, management reported a 35% RECIST response rate, 50% disease control rate, and 25% PSA90 rate in a heavily pretreated population with a median of four prior therapies; one patient had a confirmed PR and a PSA90 with response lasting over 22 weeks. Safety was described as generally manageable, with only two treatment discontinuations and one Grade 5 immune-related hepatitis event in over 240 patients treated with vudalimab to date. Looking ahead, the company expects XmAb541 to enter Phase 1 in the first half of 2024, expects significant progress this year on XmAb819 dose escalation, and plans to select the next IND candidate later in 2024.
Bassil Dahiyat framed 2024 as a year of sharper focus, saying Xencor is concentrating resources on solid-tumor bispecifics and vudalimab while pulling back on cytokine programs. He emphasized validation from partner Amgen’s Xaluritamig data and J&J’s CD28 collaboration as external support for the platform. His tone was cautious but constructive: he repeatedly said the company is encouraged by early signals, but wants more patients and follow-up before making major disclosure or development decisions.
The CFO did not give a detailed quarterly financial breakdown on the call, and no revenue, EPS, or margin data were reported. The main financial update was the strengthened balance sheet: Xencor ended 2023 with $697 million in cash and expects runway into 2027, helped by a partial monetization of Ultomiris and Monjuvi royalties and milestone/royalty income. Management also pointed to capital reallocation away from cytokines and toward T-cell engagers as a key resource decision.
Analysts focused mainly on when Xencor might disclose initial ENPP3 data and how management would judge vudalimab’s path forward. On ENPP3, management said it is not guiding to a data date yet and wants enough patients and follow-up to define the dose level and dosing regimen first. On vudalimab, management said it wants roughly 30 patients in each cohort to evaluate monotherapy and docetaxel-combination data, using historical controls such as cabazitaxel and TAX 327 as context, while also considering the evolving role of PLUVICTO and whether prior radioligand therapy could sensitize tumors to checkpoint therapy. Questions about hepatitis safety were addressed by noting the single Grade 5 case appears isolated within a complex patient course, with no broader signal seen so far and monitoring protocols aligned with NCCN/ASCO guidance.
The bull case is that Xencor has meaningful platform validation and a stronger cash position to fund a solid-tumor strategy into 2027. Management sees encouraging early clinical signals in a very difficult mCRPC population, plus progress in lung cancer and multiple bispecific programs advancing in 2024.
The bear case is that the most important clinical programs are still early, and management is explicitly withholding guidance on ENPP3 timing until more data mature. Vudalimab still has a serious safety event on record, and the company needs larger cohorts to prove that the current response signals translate into meaningful durability and survival benefit.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 74.4%
- Shares Outstanding
- 75.04M
- Float Shares
- 55.81M
of shares held by institutions
210 13F filers
Buy/sell ratio 0.57. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 12.41M | ▼ 1.24M |
| Primecap Management Co | 9.88M | ▼ 301.47K |
| Vanguard Group Inc | 7.17M | ▲ 61.69K |
| Rtw Investments, LP | 6.83M | ▲ 50.00K |
| Bvf Inc/Il | 6.23M | ▼ 906.69K |
| Ra Capital Management, L.P. | 5.27M | 0 |
| State Street Corp | 4.16M | ▼ 797.28K |
| Toronto Dominion Bank | 3.87M | ▲ 3.38M |
| Vanguard Capital Management LLC | 3.20M | ▼ 75.66K |
| Price T Rowe Associates Inc | 2.31M | ▼ 43.97K |
| Jefferies Financial Group Inc. | 2.08M | ▲ 1.36M |
| Tcg Crossover Management, LLC | 2.06M | ▼ 396.20K |
Held by 334 ETFs
Biggest fund positions in XNCR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | Cornelissen Bart Jan | sell | 10,100 |
| Nov 10, 26 | RANIERI RICHARD J | other | 27,372 |
| Nov 10, 26 | RANIERI RICHARD J | other | 11,971 |
| Nov 10, 26 | RANIERI RICHARD J | other | 21,412 |
| Nov 10, 26 | RANIERI RICHARD J | other | 15,000 |
| Nov 10, 26 | RANIERI RICHARD J | sell | 70,080 |
| Nov 10, 26 | RANIERI RICHARD J | sell | 11,172 |
| Nov 10, 26 | RANIERI RICHARD J | other | 21,412 |
| Nov 10, 26 | RANIERI RICHARD J | other | 15,000 |
| Nov 10, 26 | RANIERI RICHARD J | other | 11,971 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our XNCR coverage
Recent articles, reports, and earnings notes.

Lycia Therapeutics Prices Its IPO: A Big Bet on Protein Degradation
Lycia Therapeutics Inc. is set to list on Nasdaq on 2026-10-23, and the company has priced its IPO with 17,640,000 shares offered; the price range was not disclosed. The setup is compelling for investors who want exposure to early-stage biotech, but the story still hinges on clinical execution and platform validation.

Veraxa Biotech AG IPO: What Investors Need to Know
Veraxa Biotech AG Ordinary Shares (NASDAQ: VRXA) is expected to list on 2026-06-10, but the price range has not been disclosed. This is a SPAC business combination rather than a traditional IPO, with the story centered on a pre-commercial oncology pipeline. Bull case: a differentiated antibody-therapy platform; bear case: no product revenue yet and heavy financing needs.
Want a deeper read on XNCR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Xencor Presents Initial Plamotamab Data in Rheumatoid Arthritis at ACR Convergence 2026 and Updates Progress in First-in-Human Study of XmAb657
businesswire.com · Nov 9
Xencor (XNCR) Q3 Earnings and Revenues Beat Estimates
zacks.com · Nov 4
Xencor Reports Third Quarter 2026 Financial Results
businesswire.com · Nov 4
Xencor: 'Strong Buy' On Positive XmAb819 ESMO Data ccRCC And Potential For FDA Accelerated Approval Pathway
seekingalpha.com · Oct 26
Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer
marketbeat.com · Oct 26
Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma Transcript
seekingalpha.com · Oct 26
Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst
benzinga.com · Oct 26
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and
gurufocus.com · Oct 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.